Behavior and current management of hepatitis B virus infection
Abstract
Introduction: Viral hepatitis is a global health problem, causing high mortality and morbidity. Despite advances in the prevention, diagnosis and treatment of hepatitis B, this disease is still a concern of health authorities.
Objective: To update on current behavior and management of hepatitis B virus infection.
Methods: A bibliographic review was carried out during April and May 2021, consulting 211 articles in English and Spanish from databases such as SciELO, PubMed, Lilacs and Medigraphic, of which 30 citations were used. The combination of Boolean terms and operators and theoretical methods such as: analysis-synthesis, induction-deduction and historical-logical were used.
Results: The behavior of the infection caused by the hepatitis B virus was addressed, emphasizing its epidemiology, morphological and functional characteristics that allow its infectivity, evolution and clinical manifestations, complications, treatment and current perspectives.
Conclusions: The natural history of infection is dynamic, and clinical manifestations depend on various factors. Hepatitis B virus infection can cause complications such as liver cirrhosis and hepatocellular carcinoma, and its main route of transmission is parenterally. The diagnosis is made mainly through serological techniques. Differentiated care for groups at risk is essential and, although there is an effective vaccine, there are still cases and treatments have been developed with positive results.
DeCS: HEPATITIS B, CHRONIC/complications; HEPATITIS B, CHRONIC/drug therapy; LIVER CIRRHOSIS; CARCINOMA, HEPATOCELLULAR; REVIEW LITERATURE AS TOPIC.
Downloads
References
1. Gordillo Hernández A. Marcadores serológicos de infección por el virus de la hepatitis B en estudiantes de la Escuela Latinoamericana de Medicina. Arch méd Camagüey [Internet]. 2018 [citado 16 May 2021];22(5):694-707. Disponible en: http://revistaamc.sld.cu/index.php/amc/article/view/5582/3220
2. Organización Mundial de la Salud. Estrategia mundial del sector de la salud contra las hepatitis víricas 2016-2021 [Internet]. Ginebra: OMS; 2016 [citado 14 May 2021]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/250578/WHO-HIV-2016.06-spa.pdf
3. Toro Montoya AI, Restrepo Gutiérrez JC. Hepatitis B. Medicina&Laboratorio [Internet]. 2011 [citado 16 May 2021];17(7-8):311-29. Disponible en: https://www.medigraphic.com/pdfs/medlab/myl-2011/myl117-8b.pdf
4. Comité Asesor de Vacunas (CAV-AEP). Hepatitis B. Manual de vacunas en línea de la AEP [Internet]. Madrid: AEP; 2021 [citado 13 May 2021]. Disponible en: https://vacunasaep.org/documentos/manual/cap-29
5. Red Nacional de Vigilancia Epidemiológica. Informe Semanal de Vigilancia Epidemiológica nº 27 en España [Internet]. Madrid: Centro Nacional de Epidemiología; 2021 [citado 14 May 2021]. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Boletines/Documents/Boletin_Epidemiologico_en_red/boletines%20en%20red%202021/IS_N%C2%BA27-210706_WEB.pdf
6. Dirección de Vigilancia Epidemiológica de Enfermedades No Transmisibles. Informe Anual de Vigilancia Epidemiológica de Hepatitis Virales, México 2020 [Internet]. México: DGE; 2020 [citado 14 May 2021]. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/615926/HepatitisViralesInformeAnual2020.pdf
7. Ministerio de Salud. Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Número de casos de hepatitis B, Perú 2000-2021 [Internet]. Lima: MINSA; 2021 [citado 14 May 2021]. Disponible en: https://www.dge.gob.pe/portal/docs/vigilancia/sala/2021/SE12/hepatitisb.pdf
8. Ministerio de Salud Pública. Anuario Estadístico de Salud 2019 [Internet]. La Habana: Dirección de Registros Médicos y Estadísticas de Salud; 2020 [citado 22 Nov 2020]. Disponible en: https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf
9. Álvarez F, Cuarterolo ML, Cioc M. Hepatitis B crónica en pediatría: tratar o no tratar, esa es la pregunta. Arch Argent Pediatr [Internet]. 2021 [citado 25 May 2021];119(2):e117-e120. Disponible en: https://www.sap.org.ar/docs/publicaciones/archivosarg/2021/v119n2a10.pdf
10. Arús E, Rodríguez Lay LÁ, Almirall Carbonell P, Dorta Guridi Z, Escobedo Carbonell AA, Galbán García E, et al. Infecciones del hígado. En: Paniagua Estévez ME, Piñol Jiménez FN, editores. Gastroenterología y hepatología clínica. La Habana: ECIMED; 2016. p. 1964-2086.
11. Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol [Internet]. 2019 Jun [citado 25 May 2021];7(5):642-50. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545711/.
12. Rodríguez Lay LA. Caracterización molecular del virus de la hepatitis B: eslabón imprescindible en la eliminación de la enfermedad en Cuba. Anales de la Academia de Ciencias de Cuba [Internet]. 2016 [citado 25 May 2021];6(3I). Disponible en: http://revistaccuba.sld.cu/index.php/revacc/article/view/614
13. Consejo General de Colegios Oficiales de Farmacéuticos. Punto Farmacéutico número 136. Hepatitis virales [Internet]. Madrid: CGCOF; 2019 [citado 25 May 2021]. Disponible en: https://www.actasanitaria.com/uploads/s1/14/56/50/9/punto-farmacologico-no-136-hepatitis-virales.pdf
14. Aguilera Guirao A, Romero Yuste S, Regueiro BJ. Epidemiología y manifestaciones clínicas de las hepatitis virales. Enferm Infecc Microbiol Clin [Internet]. 2006 Abr [citado 26 May 2021];24(4):264-76. Disponible en: https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-epidemiologia-manifestaciones-clinicas-hepatitis-virales-13087299
15. Asociación Catalana de Pacientes Hepáticos. 2000-2020. Conmemoración del 20o Aniversario de ASSCAT [Internet]. Cataluña: ASSCAT; 2021 [citado 24 May 2021]. Disponible en: https://asscat-hepatitis.org/wp-content/uploads/revista-ASSCAT-25-2021-min.pdf
16. Patiño Masis J. Hepatitis B-cuadro clínico. Acta med costarric [Internet]. 2008 Nov [citado 24 May 2021];50(Suppl 3):9-11. Disponible en: https://www.scielo.sa.cr/pdf/amc/v50s3/art04v50s3.pdf
17. Cortés L, Domínguez M, Simón MA. Hepatitis B [Internet]. España: Asociación Española de Gastroenterología; 2015 [citado 24 May 2021]. Disponible en: https://www.aegastro.es/documents/pdf/53_Hepatitis_B.pdf
18. Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol [Internet]. 2018 [citado 14 Oct 2020];53(4):566-75. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866827/.
19. Comité Asesor de Vacunas (CAV-AEP). Hepatitis B. Manual de vacunas en línea de la AEP [Internet]. Madrid: AEP; 2021 [citado 23 May 2021]. Disponible en: https://vacunasaep.org/documentos/manual/cap-29
20. Dehesa Violante M. Hepatitis B. Rev Gastroenterol Méx [Internet]. 2013 [citado 25 May 2021];78(S1):90-92. Disponible en: https://www.researchgate.net/publication/276906520_Hepatitis_B
21. Gara N, Abdalla A, Rivera E, Zhao X, Werner JM, Liang TJ, et al. Durability of antibody response following hepatitis B vaccination in healthcare workers vaccinated as adults. Hepatology [Internet]. 2012 [citado 27/5/2021];56(1):905. Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.26040
22. Marcellin P, Xie Q, Woon Paik S, Flisiak R, Piratvisuth T, Petersen J, et al. S-Collate cohort real-life study efficacy and safety of peginterferon alfa 2a in 1223 patients with chronic hepatitis B according to Asian and Caucasian race. J Hepatol [Internet]. 2013 [citado 24 May 2021];58(1):18. Disponible en: https://www.journal-of-hepatology.eu/article/S0168-8278(13)60043-4/pdf
23. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in HbeAg positive chronic hepatitis B use in serum hepatitis surface antigen level: a pooled analysis of 803 patients. Hepatology [Internet]. 2012 [citado 25 May 2021];56(1):23. Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.26436
24. Chen WC, Cheng JS, Chiang PH, Tsay FW, Chan HH, Chang HW, et al. Comparison of lamivudine, telbivudine, and entecavir as antiviral prophylaxis for patients with hepatitis B undergoing cytotoxic chemotherapy. Hepatology [Internet]. 2012 [citado 24 May 2021];56(1):906. Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.26040
25. Masarone M, Persico M. Prevalence of occult HBV infection reactivation in a large cohort on non-Hodgkin lymphoma (NHL) patients: a retrospective study. Hepatology [Internet]. 2012 [citado 24 May 2021];56(1):908. Disponible en: https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.26040
26. Organización Panamericana de la Salud. Las hepatitis B y C bajo la lupa La respuesta de salud pública en la Región de las Américas [Internet]. Washington DC: OPS; 2016 [citado 23 May 2021]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/31447/9789275319291-spa.pdf?sequence=5&isAllowed=y
27. Infante-Velázquez M. Cuba, a la vanguardia en la Hepatología. Periódico Digital Centroamericano y del Caribe [Internet] 19 Abr 2021 [citado 23 May 2021]. Disponible en: https://newsinamerica.com/pdcc/boletin/2021/cuba-a-la-vanguardia-en-la-hepatologia/&ved
28. Ministerio de Salud Pública. Plan Estratégico Nacional para la prevención y control de las ITS, el VIH y las hepatitis 2019-2023. La Habana: MINSAP; 2019.
29. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis and Therapy. Clin Microbiol Rev. 2020 Feb 26;33(2): e00046-19. doi:10.1128/CMR.00046-19.
30. Tu T, Douglas MW. Special Issue Hepatitis B Virus Infection: From Diagnostics to Treatments. Viruses [Internet]. 2020 Dic [citado 24 May 20201];12(12):1366. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761508/.
Published
How to Cite
Issue
Section
License
Copyright: Camagüey Medical Archive Magazine, offers immediately after being indexed in the SciELO Project; Open access to the full text of the articles under the principle of making available and free the research to promote the exchange of global knowledge and contribute to a greater extension, publication, evaluation and extensive use of the articles that can be used without purpose As long as reference is made to the primary source.
Conflicts of interest: authors must declare in a mandatory manner the presence or not of conflicts of interest in relation to the investigation presented.
(Download Statement of potential conflicts of interest)
The Revista Archivo Médico de Camagüey is under a License Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International (CC BY 4.0).
This license allows others to distribute, to mix, to adjust and to build from its work, even for commercial purposes, as long as it is recognized the authorship of the original creation. This is the most helpful license offered. Recommended for maximum dissemination and use of licensed materials. The full license can be found at: https://creativecommons.org/licenses/
14 julio 2025